Shares of Prothena Corp. (NASDAQ:PRTA) saw unusually-strong trading volume on Friday . Approximately 508,162 shares changed hands during mid-day trading, a decline of 20% from the previous session’s volume of 632,120 shares.The stock last traded at $48.11 and had previously closed at $45.64.

Several analysts have issued reports on PRTA shares. Royal Bank Of Canada reissued a “buy” rating on shares of Prothena Corp. in a research note on Wednesday, June 22nd. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Prothena Corp. in a research note on Friday, June 10th. Zacks Investment Research raised shares of Prothena Corp. from a “sell” rating to a “hold” rating in a research note on Friday, May 6th. Wedbush reaffirmed an “outperform” rating and set a $77.00 price target on shares of Prothena Corp. in a research note on Tuesday, July 5th. Finally, Barclays PLC initiated coverage on shares of Prothena Corp. in a research note on Friday, May 13th. They set an “overweight” rating and a $60.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Prothena Corp. has an average rating of “Buy” and an average target price of $74.60.

The company has a 50-day moving average price of $43.27 and a 200 day moving average price of $42.31. The firm’s market capitalization is $1.67 billion.

Prothena Corp. (NASDAQ:PRTA) last announced its quarterly earnings data on Tuesday, May 3rd. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by $0.04. On average, analysts forecast that Prothena Corp. will post ($3.72) EPS for the current fiscal year.

In other news, Director Dennis J. Selkoe sold 5,000 shares of the stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $45.00, for a total value of $225,000.00. Following the completion of the sale, the director now owns 3,025 shares of the company’s stock, valued at approximately $136,125. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Several hedge funds have recently bought and sold shares of the stock. State Board of Administration of Florida Retirement System boosted its stake in Prothena Corp. by 4.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 17,358 shares of the company’s stock valued at $1,182,000 after buying an additional 803 shares during the period. Morgan Stanley boosted its stake in Prothena Corp. by 10.8% in the fourth quarter. Morgan Stanley now owns 18,747 shares of the company’s stock valued at $1,278,000 after buying an additional 1,830 shares during the period. ProShare Advisors LLC boosted its stake in Prothena Corp. by 11.1% in the fourth quarter. ProShare Advisors LLC now owns 29,906 shares of the company’s stock valued at $2,037,000 after buying an additional 2,990 shares during the period. Rhumbline Advisers boosted its stake in Prothena Corp. by 7.5% in the fourth quarter. Rhumbline Advisers now owns 30,805 shares of the company’s stock valued at $2,098,000 after buying an additional 2,140 shares during the period. Finally, New York State Common Retirement Fund boosted its stake in Prothena Corp. by 4.0% in the fourth quarter. New York State Common Retirement Fund now owns 31,000 shares of the company’s stock valued at $2,111,000 after buying an additional 1,200 shares during the period.

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.